Hunger hormone-based therapy for lowering cholesterol, and triglycerides levels: Ghrelin, a digestive hormone that controls appetite, decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD), via up-regulation of its target gene, 27/April/2019, 11.57 pm

PIM-1-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: PIM-1, a regulator of cell cycle progression, increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes, via up-regulation of its target gene, 27/April/2019, 11.40 pm
April 27, 2019
Natural product-based therapy for anxiety and depression: Paeonol, isolated from Paeonia suffruticosa,  decreases PHF8 levels, increases the expression of serotonin receptors Htr1a and Htr2a, and promotes resistance to stress-induced -anxiety and -depression, via down-regulation of its target gene, 27/April/2019, 12.05 am
April 27, 2019
Show all

The significance of the study:

Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in the US succumb to this disease; (3) obesity and type 2 diabetes are risk factor for the development of NAFLD;  and (4) the global economic cost spent for NAFLD is enormous, there is an urgent need to find: (i) a way to decrease cholesterol deposition in liver; (ii) a cheaper alternative to the existing expensive drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, NAFLD.


Research findings to Therapeutic opportunity:

This study suggests the hunger hormone Ghrelin-based therapy for lowering cholesterol and triglyceride levels, and to treat Non-alcoholic fatty liver disease (NAFLD).

 Ghrelin, by increasing the expression of its target gene, it may suppress the expression of HMGCR (Fig.1). Thereby, it may: (1) decrease Triglycerides, free cholesterol, and total cholesterol levels; (2) attenuate lipid deposition in the liver; and (3) inhibit progression to NAFLD (Fig. 1). Thus, a pharmaceutical formulations encompassing Ghrelin or activators, either alone or in combination with other drugs, may be used to treat NAFLD.

Figure 1. Mechanistic insights into how Ghrelin decreases the expression of HMGCR, lowers cholesterol levels, decreases triglyceride levels, and NAFLD

Figure 2.  Ghrelin  functions as a cholesterol-lowering agent. Ghrelin lowers cholesterol and triglyceride levels and attenuates NAFLD, through down-regulation of HMGCR

 


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Ghrelin decrease the expression of HMGCR and prevent NAFLD?

Amount: $750#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Hunger hormone-based therapy for lowering cholesterol, and triglycerides levels: Ghrelin, a digestive hormone that controls appetite, decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD), via up-regulation of its target gene, 27/April/2019, 11.57 pm, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite us, kindly drop us a line at info@genomediscovery.org

Comments are closed.